<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-id journal-id-type="iso-abbrev">Lipids Health Dis</journal-id><journal-title-group><journal-title>Lipids in Health and Disease</journal-title></journal-title-group><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26573152</article-id><article-id pub-id-type="pmc">4647573</article-id><article-id pub-id-type="publisher-id">150</article-id><article-id pub-id-type="doi">10.1186/s12944-015-0150-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Variant of PAI-2 gene is associated with coronary artery disease and recurrent coronary event risk in Chinese Han population</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Xia</given-names></name><address><email>250456230@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Luo</surname><given-names>Jun-Yi</given-names></name><address><email>luojunyi3130@126.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lei</given-names></name><address><email>zhangleitangtang@sina.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yi-Ning</given-names></name><address><email>yangyn5126@163.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Xiang</given-names></name><address><email>247605749@qq.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Fen</given-names></name><address><email>604760840@qq.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Bang-Dang</given-names></name><address><email>825116852@qq.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ma</surname><given-names>Yi-Tong</given-names></name><address><phone>86-991-4366169</phone><email>myt-xj@163.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Department of Geriatrics, Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011 China </aff><aff id="Aff2"><label/>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054 China </aff><aff id="Aff3"><label/>Xinjiang Key Laboratory of Cardiovascular Disease Research, Urumqi, Xinjiang 830054 China </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>14</volume><elocation-id>148</elocation-id><history><date date-type="received"><day>4</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>3</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Li et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Plasminogen activator inhibitor &#x02212;2 (PAI-2) is an important molecular that plays a crucial role in vascular homeostasis and constitutes a critical response mechanism to cardiovascular injury, such as atherosclerosis, coronary artery disease (CAD).</p></sec><sec><title>Methods</title><p>The aim of the current study was to explore the association between the variants in <italic>PAI-2</italic> gene and CAD and its prognoses. The three variants (rs8093048, rs9946657, rs9320032) of the <italic>PAI-2</italic> gene were detected in 407 patients with CAD and 518 control subjects. All patients with CAD underwent one-year follow-up for major adverse cardiac events (MACE).</p></sec><sec><title>Results</title><p>The frequencies of the TT genotype and T allele of rs8093048 was significantly higher in CAD patients than that in control subjects (7.6&#x000a0;% vs.3.5&#x000a0;%, <italic>P</italic>&#x02009;=&#x02009;0.003, 28.1&#x000a0;% vs.21.7&#x000a0;%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively). Multifactor logistic regression analysis showed that the TT genotype of rs8093048 was a risk factor for CAD (OR&#x02009;=&#x02009;1.455, 95 % CI: 1.069-1.980, <italic>P</italic>&#x02009;=&#x02009;0.017). In addition, the follow-up data showed that CAD patients with rs8093048 TT genotype had significantly higher rate of refractory angina and MACE than those with CC or CT genotype (<italic>P</italic>&#x02009;=&#x02009;0.032, <italic>P</italic>&#x02009;=&#x02009;0.009, respectively). Cox regression analysis showed that rs8093048 TT genotype was the risk factor for the MACE (Hazard ratio&#x02009;=&#x02009;5.672, 95 % CI&#x02009;=&#x02009;1.992-16.152, <italic>P</italic>&#x02009;=&#x02009;0.001).</p></sec><sec><title>Conclusion</title><p>We firstly found that the variant of <italic>PAI-2</italic> gene was associated with CAD and recurrent coronary event risk in Chinese Han population, in Xinjiang.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>PAI-2</italic> gene</kwd><kwd>Polymorphism</kwd><kwd>Coronary artery disease</kwd><kwd>Recurrent coronary event risk</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>The plasminogen activator (PA) system plays a key role in vascular homeostasis and constitutes a critical response mechanism to cardiovascular injury, such as atherosclerosis, coronary artery disease (CAD), myocardial infarction (MI) and restenosis [<xref ref-type="bibr" rid="CR1">1</xref>]. The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor &#x02212;2 (PAI-2) [<xref ref-type="bibr" rid="CR2">2</xref>]. PAI-2 is widely expressed in various cells, such as monocytes and macrophages, eosinophils, keratinocytes, microglia, and endothelial and epithelial cells, and is intensely upregulated in inflammation, infection, pregnancy, and other pathophysiological conditions [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. It is predominantly expressed as a 47&#x000a0;kDa non-glycosylated intra cellular form located in the cytoplasm, but it can also be found as a glycosylated 60&#x02013;70&#x000a0;kDa protein located in the extracellular surface [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. PAI-2 has been proposed to play a role in different processes, including protection of the retinoblastoma protein from degradation, regulation of keratinocyte and monocyte proliferation, and differentiation, priming interferon &#x003b1;/&#x003b2; responses, inhibition of annexin-1 cleavage, interleukin 1&#x003b2; processing, promotion of adipose tissue development, and the inhibition of apoptosis [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>CAD is a complex and multifactorial disorder involving the interaction of genetic factors and environmental factors. Despite significant improvement in clinical management of the CAD, it is still reported as the most common cause of adult deaths worldwide [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. While lifestyle modification has reduced the mortality rate, the candidate gene approach has provided new insights for exploring diagnostic and therapeutic approaches. <italic>PAI-2</italic> gene consists of 8 exons spanning 16.18&#x000a0;kb on the long arm of chromosome 18 [<xref ref-type="bibr" rid="CR11">11</xref>]. Nur Buyru et al. investigated 45 myocardial infarction patients and 20 control subjects, they found that the variant at the 413 position (AA genotype) of <italic>PAI-2</italic> gene was associated with an increased risk of MI [<xref ref-type="bibr" rid="CR12">12</xref>]. James P. Corsetti et al. found that the polymorphism of rs6095 in <italic>PAI-2</italic> gene was the continued significant risk of recurrent coronary event among 166 patients with high high-density lipoprotein-cholesterol (HDL-C) and C-reactive protein levels [<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, Zhao et al. genotyped 57 patients with CAD and 62 controls, it indicated that <italic>PAI-2</italic> gene Ser/Cys413 15588&#x000a0;G/C polymorphism was associated with CAD and the C allele was a risk factor for CAD [<xref ref-type="bibr" rid="CR14">14</xref>]. In the current study, we recruited a larger sample (407 CAD patients and 518 control subjects) to investigate the association between <italic>PAI-2</italic> gene and CAD in Chinese Han population. And we built a prospective cohort study of the CAD patients to analyze the major adverse cardiac events (MACE) among different genotypes of PAI-2 gene for a mean period of one-year follow-up.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Ethics statement</title><p>Written informed consents were obtained from all the participants. The study was approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University and conducted according to the principles outlined in the Declaration of Helsinki.</p></sec><sec id="Sec4"><title>Subjects</title><p>All CAD patients and control subjects were recruited at the First Affiliated Hospital of Xinjiang Medical University from 2010 to 2013. 407 CAD patients and 518control subjects were randomly recruited in this study. All of the participants were genetically-unrelated. All of the CAD patients were defined by angiographic means (main coronary artery stenosis of &#x0003e;50&#x000a0;%). For the control group, we selected healthy participants matched for sex, and age. Control subjects were selected from the Cardiovascular Risk Survey (CRS) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Briefly, the CRS is a prospective, observational cohort study designed to investigate the prevalence, incidence, and risk factors for cardiovascular disease in the Han, Uygur, and Kazakh populations in Xinjiang of China. The control participants were defined as with no coronary vessel stenosis or clinical and electrocardiographic evidence of MI or CAD. All patients with kidney disease, malignancy, connective tissue disease, schizophrenia, or chronic inflammatory disease were excluded.</p></sec><sec id="Sec5"><title>Laboratory examination and definition of cardiovascular risk factors</title><p>The plasma concentration of blood triglyceride (TG), total cholesterol (TC), HDL-C, and low-density lipoprotein-cholesterol (LDL-C), were measured using standard methods in the Clinical Laboratory Department of First Affiliated Hospital, Xinjiang Medical University. Hypertension was defined as history of hypertension and/or an average systolic blood pressure (SBP)&#x02009;&#x02265;&#x02009;140&#x000a0;mmHg and/or an average diastolic blood pressure (DBP) &#x02265;90&#x000a0;mmHg on at least 2 separate occasions according to the medical examination and history. Diabetes was defined as history or presence of diabetes and/or a fasting plasma glucose level &#x0003e;7.0&#x000a0;mmol/L (126&#x000a0;mg/dl) on 2 separate occasions, or a random glucose value of &#x0003e;11.1&#x000a0;mmol/L (200&#x000a0;mg/dl) on &#x02265;1 occasion. Body mass index (BMI) was calculated from standardized measurements of height and weight. Persons reporting regular tobacco use in the previous 6&#x000a0;months were considered as current smokers.</p></sec><sec id="Sec6"><title>DNA Extraction</title><p>Blood samples were collected from all participants after fasting for 12&#x000a0;h. Genome DNA was extracted from peripheral vein blood leukocytes using a whole blood genome extraction kit (Boiteke Corporation, Beijing, China).</p></sec><sec id="Sec7"><title>SNP selection</title><p>In this study, we screened the data on the National Center for Biotechnology Information SNP database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP">www.ncbi.nlm.nih.gov/SNP</ext-link>) for the SNPs of <italic>PAI-2</italic> gene. There are 141 SNPs listed in the SNP database. We used the minor allele frequency (MAF) &#x02265;0.1 and linkage disequilibrium patterns with r<sup>2</sup>&#x02009;&#x02265;&#x02009;0.5 as a cut off by the Haploview 4.2 software. We achieved 7 tag SNPs listed in the HapMap phrase II database. SNPs with relatively high MAF have been shown to be useful as genetic markers in genetic association studies. Based on the screening for markers to be used in our genetic association research, we selected 3 SNPs (rs9946657, rs8093048, rs9320032) which located in a haplotype region. rs8093048 located in the 3&#x02019;untranslated region (UTR) of the flotillin-2 gene, rs9320032 located in the intron, and rs9946657 located in the 5&#x02019; UTR.</p></sec><sec id="Sec8"><title>Genotyping</title><p>We used TaqMan&#x000ae; SNP genotyping assays (Applied Biosystems, Foster City, CA). The primers and probes used in the TaqMan&#x000ae; SNP Genotyping Assays were chosen based on information available at the ABI website. The polymerase chain reaction (PCR) amplification was performed in 96 well plates adding 2.5&#x000a0;&#x003bc;L of TaqMan Universal Master Mix (40&#x000d7;), 0.15&#x000a0;&#x003bc;L probes and 1.85&#x000a0;&#x003bc;L ddH2O in a 6&#x000a0;&#x003bc;L final reaction volume containing 1.5&#x000a0;&#x003bc;L DNA. Separate negative control group and positive control group in each plate. The PCR amplification was performed using the 7900HT sequence detection system and the amplified condition was as follows: 95&#x000a0;&#x000b0;C for 5&#x000a0;min; 40&#x000a0;cycles of 95&#x000a0;&#x000b0;C for 15&#x000a0;s; and 60&#x000a0;&#x000b0;C for 1&#x000a0;min. All 96 well plates were read on Sequence Detection Systems (SDS) automation controller software v2.3 (ABI).</p></sec><sec id="Sec9"><title>Clinical follow-up and judgment of endpoint events</title><p>Follow-up examination was performed on one year after discharge. Follow-up information was collected through out-patient review, telephone call, and readmission. Record the general information of the patients and the end point events. The primary end point used was MACE, defined as death, refractory angina, MI, target vessel revascularization (TVR), and cerebrovascular events [transient ischemic attack (TIA), stroke and reversible ischemic injury].</p></sec><sec id="Sec10"><title>Statistical analysis</title><p>All analyses were performed using the computer software Statistical Package for Social Sciences-SPSS for Windows (version 17.0). Hardy-Weinberg equilibrium was assessed by using chi-square analysis. Continuous data were expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) and the differences between the CAD patients and the control participants were assessed by independent samples <italic>t</italic> test. Categorical data and distribution of genotypes and alleles were shown as percentages (%) and the differences between the two groups were assessed by chi-square test. Logistic regression analysis was performed to assess the contribution of the major risk factor to CAD and the value was shown as odds ratio (OR) and its 95&#x000a0;% confidence interval (CI). In addition, the COX regressive analysis was used to assess the clinical prognosis among different genotype of Flotillin-2 gene. <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered to indicate a statistically significant difference.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Characteristics of participants</title><p>A total of 925 individuals (407 patients with CAD and 518 healthy controls) were participated in this study. There were no differences in age between CAD patients and control subjects, suggesting that the study was an age&#x02011;matched case&#x02011;control study. The concentration of HDL-C was significantly lower in patients with CAD than that in control subjects (<italic>P</italic>&#x02009;=&#x02009;0.026). However, the percentage of individuals with EH, DM and smoking were significantly higher in CAD patients than that in control subjects (<italic>P</italic>&#x02009;=&#x02009;0.013, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively). No significant differences in BMI, pulse and concentration of TC, TG, LDL-C were observed between the two groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of study participants in Chinese Han population</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>CAD patients</th><th>Control subjects</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Number of subjects</td><td>407</td><td>518</td><td/></tr><tr><td>Age(years)</td><td>62.36(10.62)</td><td>62.40(9.45)</td><td>0.951</td></tr><tr><td>Men, n (%)</td><td>290(71.3)</td><td>348(67.2)</td><td>0.184</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.70(3.38)</td><td>26.06(4.10)</td><td>0.153</td></tr><tr><td>Pulse (beats/min)</td><td>73.04(10.42)</td><td>72.72(10.32)</td><td>0.641</td></tr><tr><td>TC (mmol/L)</td><td>4.44(0.97)</td><td>4.33(1.03)</td><td>0.165</td></tr><tr><td>TG (mmol/L)</td><td>1.84(1.23)</td><td>1.91(1.62)</td><td>0.470</td></tr><tr><td>LDL (mmol/L)</td><td>2.46(0.91)</td><td>2.44(0.84)</td><td>0.824</td></tr><tr><td>HDL (mmol/L)</td><td>1.16(0.49)</td><td>1.24(0.58)</td><td>0.026*</td></tr><tr><td>EH,n (%)</td><td>219(53.8)</td><td>236(45.6)</td><td>0.013*</td></tr><tr><td>DM, n (%)</td><td>107(26.3)</td><td>61(11.8)</td><td>&#x0003c;0.001*</td></tr><tr><td>Smoking, n (%)</td><td>233(57.2)</td><td>184(35.5)</td><td>&#x0003c;0.001*</td></tr></tbody></table><table-wrap-foot><p>Continuous variables are expressed as mean&#x02009;&#x000b1;&#x02009;s.d. Categorical variables are expressed as percentages. <italic>CAD</italic> coronary artery disease, <italic>BMI</italic> body mass index, <italic>total TC</italic> cholesterol, <italic>TG</italic> triglycerides, <italic>LDL-C</italic> Low-density lipoprotein-cholesterol, <italic>HDL-C</italic> high-density lipoprotein-cholesterol, <italic>EH</italic> essential hypertension, <italic>DM</italic> diabetes mellitus. The <italic>P</italic> value of the continuous variables was calculated by the independent samples <italic>t</italic> test. The <italic>P</italic> value of the categorical variables was calculated by Chi square test. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Distribution of the flotillin-2 genotype</title><p>The genotype distribution of the three SNPs in <italic>PAI-2</italic> gene did not show any significant difference from Hardy-Weinberg equilibrium (all <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, the data did not show). The frequency of genotype and allele of <italic>PAI-2</italic> gene in CAD patients and controls were shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. There were significant differences in genotypic and allelic distribution of <italic>PAI-2</italic> gene between CAD patients and controls. The <italic>PAI-2</italic> gene rs8093048 TT genotype and T allele distribution was significantly higher in CAD patients than that in control subjects (7.6&#x000a0;% versus 3.5&#x000a0;%, <italic>P</italic>&#x02009;=&#x02009;0.003, 28.1&#x000a0;% versus 21.7&#x000a0;%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively). For rs9946657 and rs9320032, we did not found any significant difference in the genotypic and allelic distribution of <italic>PAI-2</italic> gene between CAD patients and controls.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Genotype and allele distributions of PAI-2 gene in CAD patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variants</th><th>Genotyping/allele</th><th>CAD patients</th><th>Control subjects</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>rs9946657</td><td>GG</td><td>114(28.0&#x000a0;%)</td><td>155(29.9&#x000a0;%)</td><td/></tr><tr><td/><td>GT</td><td>211(51.8&#x000a0;%)</td><td>273(52.7&#x000a0;%)</td><td/></tr><tr><td/><td>TT</td><td>82(20.2&#x000a0;%)</td><td>90(17.4&#x000a0;%)</td><td>0.532</td></tr><tr><td/><td>T</td><td>375(46.1&#x000a0;%)</td><td>453(43.7&#x000a0;%)</td><td/></tr><tr><td/><td>G</td><td>439(53.9)</td><td>583(56.3&#x000a0;%)</td><td>0.314</td></tr><tr><td>rs8093048</td><td>CC</td><td>209(51.4&#x000a0;%)</td><td>311(60.0&#x000a0;%)</td><td/></tr><tr><td/><td>CT</td><td>167(41.0&#x000a0;%)</td><td>189(36.5&#x000a0;%)</td><td/></tr><tr><td/><td>TT</td><td>31(7.6&#x000a0;%)</td><td>18(3.5&#x000a0;%)</td><td>0.003</td></tr><tr><td/><td>C</td><td>585(71.9&#x000a0;%)</td><td>811(78.3&#x000a0;%)</td><td/></tr><tr><td/><td>T</td><td>229(28.1&#x000a0;%)</td><td>225(21.7&#x000a0;%)</td><td>&#x0003c;0.001*</td></tr><tr><td>rs9320032</td><td>CC</td><td>13(3.2&#x000a0;%)</td><td>18(3.5&#x000a0;%)</td><td/></tr><tr><td/><td>CT</td><td>119(29.2&#x000a0;%)</td><td>152(29.3&#x000a0;%)</td><td/></tr><tr><td/><td>TT</td><td>275(67.6&#x000a0;%)</td><td>348(67.2&#x000a0;%)</td><td>0.828</td></tr><tr><td/><td>C</td><td>145(17.8&#x000a0;%)</td><td>188(18.1&#x000a0;%)</td><td/></tr><tr><td/><td>T</td><td>669(82.2&#x000a0;%)</td><td>848(81.9&#x000a0;%)</td><td>0.853</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>Logistic regression analysis of CAD risk factors</title><p>Multifactor logistic regression analyzed the contribution of the major risk factor to CAD. It showed that rs8093048 T allele carriers (TT&#x02009;+&#x02009;CT), DM, and smoking were the risk factors for CAD. Following adjustments for DM, EH, TC, LDL-C, HDL-C, and smoking, the subjects with T allele of rs8093048 (TT&#x02009;+&#x02009;CT) had a significantly higher risk of CAD (OR&#x02009;=&#x02009;1.455, 95 % CI: 1.069-1.980, <italic>P</italic>&#x02009;=&#x02009;0.017) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Multiple logistic regression analysis for CAD patients and control subjects in Chinese Han population</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Risk factors</th><th>Odd ratios</th><th>95 % CI</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>rs8093048 (TT&#x02009;+&#x02009;CT v.s. CC)</td><td char="." align="char">1.455</td><td>1.069-1.980</td><td>0.017*</td></tr><tr><td>DM</td><td char="." align="char">1.724</td><td>1.174-2.531</td><td>0.005*</td></tr><tr><td>Hypertension</td><td char="." align="char">1.263</td><td>0.925-1.725</td><td>0.142</td></tr><tr><td>TC</td><td char="." align="char">1.165</td><td>0.951-1.429</td><td>0.141</td></tr><tr><td>LDL</td><td char="." align="char">0.916</td><td>0.726-1.155</td><td>0.457</td></tr><tr><td>HDL</td><td char="." align="char">0.805</td><td>0.60-1.079</td><td>0.146</td></tr><tr><td>Smoking</td><td char="." align="char">3.506</td><td>2.564-4.794</td><td>&#x0003c;0.001*</td></tr></tbody></table><table-wrap-foot><p>
<italic>CAD</italic> coronary artery disease, <italic>DM</italic> diabetes mellitus, <italic>LDL-C</italic> Low-density lipoprotein-cholesterol, <italic>HDL-C</italic> high-density lipoprotein-cholesterol. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Result of clinical follow-up</title><p>One year follow-up data were available in 397 of the original 407 CAD patients (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The missing rate was 2.46&#x000a0;%. Overall, 27 MACE occurred during the one-year study (6.8&#x000a0;%). There were 4 patients died (1.0&#x000a0;%), 6 patients occurred refractory angina (1.5&#x000a0;%), 5 patients had MI (1.25&#x000a0;%), 4 patients had target vessel revascularization (1.0&#x000a0;%), 8 patients occurred cerebrovascular events (2.0&#x000a0;%). The rate of refractory angina and MACE were significantly different among the three different genotype of rs8093048 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Cox regression analysis showed that rs8093048 TT genotype was the risk factor for the MACE (Hazard ratio&#x02009;=&#x02009;5.672, 95 % CI&#x02009;=&#x02009;1.992-16.152, <italic>P</italic>&#x02009;=&#x02009;0.001) (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>The occurrence of adverse events in patients with CAD during one year follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th>End point</th><th>CC(204)</th><th>CT(163)</th><th>TT(30)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Death, n (%)</td><td>2(1.0)</td><td>1(0.6)</td><td>1(3.3)</td><td char="." align="char">0.39</td></tr><tr><td>refractory angina, n (%)</td><td>1(0.5)</td><td>3(1.8)</td><td>2(6.7)</td><td char="." align="char">0.032*</td></tr><tr><td>MI, n (%)</td><td>2(1.0)</td><td>2(1.2)</td><td>1(3.3)</td><td char="." align="char">0.558</td></tr><tr><td>TVR, n (%)</td><td>1(0.5)</td><td>2(1.2)</td><td>1(3.3)</td><td char="." align="char">0.324</td></tr><tr><td>cerebrovascular events, n (%)</td><td>4(2.0)</td><td>3(1.8)</td><td>1(3.3)</td><td char="." align="char">0.864</td></tr><tr><td>MACE, n (%)</td><td>10(4.9)</td><td>11(6.7)</td><td>6(20.0)</td><td char="." align="char">0.009*</td></tr></tbody></table><table-wrap-foot><p>
<italic>MI</italic> myocardial infarction, <italic>TVR</italic> target vessel revascularization. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>The survival among different genotype of rs8093048 in Chinese Han CAD patients</p></caption><graphic xlink:href="12944_2015_150_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab5"><label>Table 5</label><caption><p>COX regression analysis in Chinese Han CAD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>
<italic>OR</italic>
</th><th>SE</th><th>
<italic>P</italic> value</th><th>Hazard ratio(95 % <italic>CI</italic>)</th></tr></thead><tbody><tr><td>BMI</td><td>0.04</td><td>0.061</td><td>0.514</td><td>1.041(0.923-1.174)</td></tr><tr><td>TG</td><td>0.069</td><td>0.174</td><td>0.694</td><td>1.071(0.761-1.507)</td></tr><tr><td>TC</td><td>&#x02212;0.054</td><td>0.257</td><td>0.833</td><td>0.947(0.573-1.567)</td></tr><tr><td>LDL-C</td><td>0.328</td><td>0.252</td><td>0.193</td><td>1.388(0.847-2.274)</td></tr><tr><td>HDL-C</td><td>0.123</td><td>0.384</td><td>0.749</td><td>1.131(0.533-2.399)</td></tr><tr><td>Hypertension</td><td>0.06</td><td>0.413</td><td>0.884</td><td>1.062(0.473-2.387)</td></tr><tr><td>DM</td><td>0.647</td><td>0.415</td><td>0.119</td><td>1.909(0.847-4.304)</td></tr><tr><td>Smoking</td><td>0.274</td><td>0.442</td><td>0.536</td><td>1.315(0.552-3.128)</td></tr><tr><td>rs8093048 genotype</td><td/><td/><td/><td/></tr><tr><td>CC</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CT</td><td>0.38</td><td>0.445</td><td>0.393</td><td>1.463(0.611-3.501)</td></tr><tr><td>TT</td><td>1.736</td><td>0.534</td><td>0.001*</td><td>5.672(1.992-16.152)</td></tr></tbody></table><table-wrap-foot><p>
<italic>BMI</italic> body mass index, <italic>TC</italic> cholesterol, <italic>TG</italic> triglycerides, <italic>LDL-C</italic> Low-density lipoprotein-cholesterol, <italic>HDL-C</italic> high-density lipoprotein-cholesterol, <italic>DM</italic> diabetes mellitus. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec16"><title>Discussion</title><p>In the current study, we observed that the variation in the <italic>PAI-2</italic> gene was associated with CAD and its prognosis in Chinese Han subjects. Individuals with TT genotype of rs8093048 had significantly higher risk of CAD and worse prognosis than that with CC or CT genotype. The rate of refractory angina was significantly higher in CAD patients with TT genotype than that with CC or CT genotype. The results demonstrated that the polymorphism of <italic>PAI-2</italic> gene may be as a marker of CAD and its prognosis.</p><p>PAI-2 is an important molecular of the serpin superfamily. It&#x02019;s an efficient inhibitor of t-PA and u-PA and an important regulatory element in fibrinolysis. To maintain normal blood flow, fibrinolysis and hemostasis should exist in a precise balance in which fibrinolysis restricts excessive blood clots and hemostasis prevents excessive blood loss. Because serine proteases in both fibrinolysis and hemostasis are the key enzymes, both processes are primarily controlled by serine protease inhibitors (serpins, such as PAI-1, PAI-2, &#x003b1;2-AP) [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. Genetic deficiency, excessive expression, or dysfunction of one or more of these serpins may cause pathological bleeding or thrombosis. In normal physiological conditions, PAI-2 is only detectable in plasma during pregnancy and probably has a role in maintaining the placenta or in embryonic development [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. It&#x02019;s worth noting that there was strong correlation between elevated tPA and PAI-2 levels in gingival crevicular fluid during inflammation, and the balance between them remains constant during the inflammatory process [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Moreover, the overexpression of PAI-2 could inhibit the proliferation and migration and promotes the apoptosis of human pulmonary arterial smooth muscle cells [<xref ref-type="bibr" rid="CR25">25</xref>]. Intracellular PAI-2 affects cellular proliferation and differentiation, alters gene expression, and inhibits apoptosis [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p>But so far, the reason and mechanism of PAI-2 and CAD are unclear. We firstly indicated that <italic>PAI-2</italic> gene may be a candidate gene of CAD in Chinese Han population. It was consistent with the previous researches. Cerrahpasa et al. found that AA genotype of the <italic>PAI-2</italic> gene was found to be more frequent among those subjects with MI [<xref ref-type="bibr" rid="CR12">12</xref>]. James et al. demonstrated independent association of the <italic>PAI-2</italic> polymorphism reference allele with recurrent cardiovascular disease risk [<xref ref-type="bibr" rid="CR13">13</xref>]. Zhao et al. reported that <italic>PAI-2</italic> gene Ser/Cys413 polymorphism is associated with CAD, the C allele is a risk factor for CAD and the G allele is a protective factor for CAD [<xref ref-type="bibr" rid="CR14">14</xref>]. However, the Physician&#x02019;s Health Study and ECTIM did not support an association between polymorphism <italic>PAI-2</italic> and acute coronary syndrome [<xref ref-type="bibr" rid="CR17">17</xref>]. The contradiction may lie in the differences in gene expression between different ethnic population and the small &#x0003e;sample in the two studies. In the other hand, Palafox-Sa&#x000b4;nchez found that the functional Ser(413)/Ser(413) <italic>PAI-2</italic> polymorphism was associated with susceptibility and damage index score in systemic lupus erythematosus [<xref ref-type="bibr" rid="CR28">28</xref>]. Moreover, the polymorphism of <italic>PAI-2</italic> gene was also associated with antiphospholipid syndrome [<xref ref-type="bibr" rid="CR29">29</xref>]. These disease states all relate to disorders in hemostasis, highlighting the role of <italic>PAI-2</italic> gene in this system.</p><p>There were certain limitations in our study. Firstly, we only detected the association between the 3 SNPs in <italic>PAI-2</italic> gene with the CAD. As we know, SNPs are the most abundant form of genetic variations and have a great potential for mapping genes underlying complex genetic traits. But their effects were micro-effect. Much more studies of the other SNPs are needed to investigate the mechanism of CAD and <italic>PAI-2</italic> gene. Secondly, the level of plasma concentration of PAI-2 was not measured in our study because of their low concentrations. However, there was an advantage in the present study what the sample size was relatively large. It was better to indicate the association between <italic>PAI-2</italic> gene and CAD.</p></sec><sec id="Sec17"><title>Conclusions</title><p>In conclusion, we are more convinced that the variant in <italic>PAI-2</italic> gene may be associated with the susceptibility to CAD and its prognosis in Chinese Han population. Individuals with rs8093048 TT and CT genotype had significantly higher risk of CAD and worse prognosis than that with CC genotype. The rate of refractory angina was significantly higher in CAD patients with TT genotype than that with CC or CT genotype.</p></sec></body><back><fn-group><fn><p>Xia Li and Jun-Yi Luo contributed equally to this work.</p></fn><fn><p><bold>Competing interest</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>Xia Li and Jun-Yi Luo carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. Lei Zhang and Yi-Ning Yang participated in the sequence alignment. Yi-Tong Ma and Fen Liu participated in the design of the study and performed the statistical analysis. Xiang Xie and Bang-Dang Chen conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgement</title><p>This study was supported by a grant from the Science Foundation of Xinjiang Uygur Autonomous Region (No. 2015211C166).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholl</surname><given-names>SM</given-names></name><name><surname>Roztocil</surname><given-names>E</given-names></name><name><surname>Davies</surname><given-names>MG</given-names></name></person-group><article-title>Plasminogen activator system and vascular disease</article-title><source>Curr Vasc Pharmacol</source><year>2006</year><volume>4</volume><issue>2</issue><fpage>101</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.2174/157016106776359880</pub-id><pub-id pub-id-type="pmid">16611153</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boncela</surname><given-names>J</given-names></name><name><surname>Przygodzka</surname><given-names>P</given-names></name><name><surname>Wyroba</surname><given-names>E</given-names></name><name><surname>Papiewska-Pajak</surname><given-names>I</given-names></name><name><surname>Cierniewski</surname><given-names>CS</given-names></name></person-group><article-title>Secretion of SerpinB2 from endothelial cells activated with inflammatory stimuli</article-title><source>Exp Cell Res</source><year>2013</year><volume>319</volume><issue>8</issue><fpage>1213</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2013.02.018</pub-id><pub-id pub-id-type="pmid">23474086</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>H</given-names></name><name><surname>Jamieson</surname><given-names>A</given-names></name><name><surname>Booth</surname><given-names>NA</given-names></name></person-group><article-title>Regulation, location and activity of plasminogen activator inhibitor 2 (PAI-2) in peripheral blood monocytes, macrophages and foam cells</article-title><source>Thromb Haemost</source><year>1997</year><volume>77</volume><issue>6</issue><fpage>1168</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">9241752</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swartz</surname><given-names>JM</given-names></name><name><surname>Bystrom</surname><given-names>J</given-names></name><name><surname>Dyer</surname><given-names>KD</given-names></name><name><surname>Nitto</surname><given-names>T</given-names></name><name><surname>Wynn</surname><given-names>TA</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name></person-group><article-title>Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes</article-title><source>J Leukoc Biol</source><year>2004</year><volume>76</volume><issue>4</issue><fpage>812</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1189/jlb.0304182</pub-id><pub-id pub-id-type="pmid">15277569</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>NA</given-names></name><name><surname>Lapic</surname><given-names>S</given-names></name><name><surname>Welter</surname><given-names>JF</given-names></name><name><surname>Eckert</surname><given-names>RL</given-names></name></person-group><article-title>S100A11, S100A10, annexin I, desmosomal proteins, small proline-rich proteins, plasminogen activator inhibitor-2, and involucrin are components of the cornified envelope of cultured human epidermal keratinocytes</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><issue>18</issue><fpage>12035</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.18.12035</pub-id><pub-id pub-id-type="pmid">9115270</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genton</surname><given-names>C</given-names></name><name><surname>Kruithof</surname><given-names>EK</given-names></name><name><surname>Schleuning</surname><given-names>WD</given-names></name></person-group><article-title>Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells</article-title><source>J Cell Biol</source><year>1987</year><volume>104</volume><issue>3</issue><fpage>705</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1083/jcb.104.3.705</pub-id><pub-id pub-id-type="pmid">3102504</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruithof</surname><given-names>EK</given-names></name><name><surname>Baker</surname><given-names>MS</given-names></name><name><surname>Bunn</surname><given-names>CL</given-names></name></person-group><article-title>Biological and clinical aspects of plasminogen activator inhibitor type 2</article-title><source>Blood</source><year>1995</year><volume>86</volume><issue>11</issue><fpage>4007</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">7492756</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boncela</surname><given-names>J</given-names></name><name><surname>Przygodzka</surname><given-names>P</given-names></name><name><surname>Papiewska-Pajak</surname><given-names>I</given-names></name><name><surname>Wyroba</surname><given-names>E</given-names></name><name><surname>Cierniewski</surname><given-names>CS</given-names></name></person-group><article-title>Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><issue>50</issue><fpage>43164</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.245647</pub-id><pub-id pub-id-type="pmid">21976669</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>CJ</given-names></name><name><surname>Nabel</surname><given-names>EG</given-names></name></person-group><article-title>Genomics of cardiovascular disease</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>22</issue><fpage>2098</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1105239</pub-id><pub-id pub-id-type="pmid">22129254</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>IM</given-names></name><name><surname>Sesso</surname><given-names>HD</given-names></name><name><surname>Oguma</surname><given-names>Y</given-names></name><name><surname>Paffenbarger</surname><given-names>RS</given-names><suffix>Jr</suffix></name></person-group><article-title>Relative intensity of physical activity and risk of coronary heart disease</article-title><source>Circulation</source><year>2003</year><volume>107</volume><issue>8</issue><fpage>1110</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000052626.63602.58</pub-id><pub-id pub-id-type="pmid">12615787</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>AC</given-names></name><name><surname>Collins</surname><given-names>KL</given-names></name><name><surname>Snyder</surname><given-names>SE</given-names></name><name><surname>Alexander</surname><given-names>SJ</given-names></name><name><surname>Rosenwasser</surname><given-names>LJ</given-names></name><name><surname>Eddy</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Human monocyte Arg-Serpin cDNA. Sequence, chromosomal assignment, and homology to plasminogen activator-inhibitor</article-title><source>J Exp Med</source><year>1987</year><volume>166</volume><issue>1</issue><fpage>77</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1084/jem.166.1.77</pub-id><pub-id pub-id-type="pmid">3496414</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buyru</surname><given-names>N</given-names></name><name><surname>Altinisik</surname><given-names>J</given-names></name><name><surname>Gurel</surname><given-names>CB</given-names></name><name><surname>Ulutin</surname><given-names>T</given-names></name></person-group><article-title>PCR-RFLP detection of PAI-2 variants in myocardial infarction</article-title><source>Clin Appl Thromb Hemost</source><year>2003</year><volume>9</volume><issue>4</issue><fpage>333</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1177/107602960300900409</pub-id><pub-id pub-id-type="pmid">14653443</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corsetti</surname><given-names>JP</given-names></name><name><surname>Salzman</surname><given-names>P</given-names></name><name><surname>Ryan</surname><given-names>D</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Sparks</surname><given-names>CE</given-names></name></person-group><article-title>Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>7</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0068920</pub-id><pub-id pub-id-type="pmid">23874812</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nan</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name></person-group><article-title>Association between PAI-2 gene polymorphism and coronary heart disease</article-title><source>Int J Cardiovasc Dis</source><year>2008</year><volume>35</volume><issue>15</issue><fpage>312</fpage><lpage>315</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>YT</given-names></name><name><surname>Yang</surname><given-names>YN</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Alcohol consumption and ankle-to-brachial index: results from the Cardiovascular Risk Survey</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><issue>12</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0015181</pub-id><pub-id pub-id-type="pmid">21152041</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>ZX</given-names></name><name><surname>Ma</surname><given-names>YT</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>YN</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><etal/></person-group><article-title>Appropriate body mass index and waist circumference cutoffs for categorization of overweight and central adiposity among Uighur adults in Xinjiang</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>11</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0080185</pub-id><pub-id pub-id-type="pmid">24244645</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gettins</surname><given-names>PG</given-names></name></person-group><article-title>Serpin structure, mechanism, and function</article-title><source>Chem Rev</source><year>2002</year><volume>102</volume><issue>12</issue><fpage>4751</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1021/cr010170+</pub-id><pub-id pub-id-type="pmid">12475206</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>ST</given-names></name><name><surname>Gettins</surname><given-names>PG</given-names></name></person-group><article-title>Regulation of proteases by protein inhibitors of the serpin superfamily</article-title><source>Prog Mol Biol Transl Sci.</source><year>2011</year><volume>99</volume><fpage>185</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-385504-6.00005-1</pub-id><pub-id pub-id-type="pmid">21238937</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rau</surname><given-names>JC</given-names></name><name><surname>Beaulieu</surname><given-names>LM</given-names></name><name><surname>Huntington</surname><given-names>JA</given-names></name><name><surname>Church</surname><given-names>FC</given-names></name></person-group><article-title>Serpins in thrombosis, hemostasis and fibrinolysis</article-title><source>J Thromb Haemost.</source><year>2007</year><volume>5</volume><issue>Suppl 1</issue><fpage>102</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2007.02516.x</pub-id><pub-id pub-id-type="pmid">17635716</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huntington</surname><given-names>JA</given-names></name></person-group><article-title>Mechanisms of glycosaminoglycan activation of the serpins in hemostasis</article-title><source>J Thromb Haemost</source><year>2003</year><volume>1</volume><issue>7</issue><fpage>1535</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1046/j.1538-7836.2003.00305.x</pub-id><pub-id pub-id-type="pmid">12871289</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecander</surname><given-names>I</given-names></name><name><surname>Astedt</surname><given-names>B</given-names></name></person-group><article-title>Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma</article-title><source>Br J Haematol</source><year>1986</year><volume>62</volume><issue>2</issue><fpage>221</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.1986.tb02925.x</pub-id><pub-id pub-id-type="pmid">3484964</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>BJ</given-names></name><name><surname>Missfelder-Lobos</surname><given-names>H</given-names></name><name><surname>Parra-Cordero</surname><given-names>M</given-names></name><name><surname>Fletcher</surname><given-names>O</given-names></name><name><surname>Parmar</surname><given-names>K</given-names></name><name><surname>Lefkou</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women undergoing uterine artery Doppler screening at 23&#x000a0;weeks</article-title><source>J Thromb Haemost</source><year>2009</year><volume>7</volume><issue>6</issue><fpage>955</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03344.x</pub-id><pub-id pub-id-type="pmid">19320824</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinnby</surname><given-names>B</given-names></name></person-group><article-title>The plasminogen activating system in periodontal health and disease</article-title><source>Biol Chem</source><year>2002</year><volume>383</volume><issue>1</issue><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1515/BC.2002.008</pub-id><pub-id pub-id-type="pmid">11928825</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Bunn</surname><given-names>CL</given-names></name><name><surname>Bartold</surname><given-names>PM</given-names></name></person-group><article-title>Detection of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2(PAI-2) in gingival crevicular fluid from healthy, gingivitis and periodontitis patients</article-title><source>J Clin Periodontol</source><year>2000</year><volume>27</volume><issue>3</issue><fpage>149</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1034/j.1600-051x.2000.027003149.x</pub-id><pub-id pub-id-type="pmid">10743860</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhai</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><etal/></person-group><article-title>The sGC activator inhibits the proliferation and migration, promotes the apoptosis of human pulmonary arterial smooth muscle cells via the up regulation of plasminogen activator inhibitor-2</article-title><source>Exp Cell Res</source><year>2015</year><volume>332</volume><issue>2</issue><fpage>278</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2015.02.006</pub-id><pub-id pub-id-type="pmid">25704756</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaller</surname><given-names>J</given-names></name><name><surname>Gerber</surname><given-names>SS</given-names></name></person-group><article-title>The plasmin-antiplasmin system: structural and functional aspects</article-title><source>Cell Mol Life Sci</source><year>2011</year><volume>68</volume><issue>5</issue><fpage>785</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1007/s00018-010-0566-5</pub-id><pub-id pub-id-type="pmid">21136135</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JA</given-names></name><name><surname>Cochran</surname><given-names>BJ</given-names></name><name><surname>Lobov</surname><given-names>S</given-names></name><name><surname>Ranson</surname><given-names>M</given-names></name></person-group><article-title>Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma</article-title><source>Semin Thromb Hemost</source><year>2011</year><volume>37</volume><issue>4</issue><fpage>395</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1276589</pub-id><pub-id pub-id-type="pmid">21805446</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isordia-Salas</surname><given-names>I</given-names></name><name><surname>Mendoza-Valdez</surname><given-names>AL</given-names></name><name><surname>Almeida-Gutierrez</surname><given-names>E</given-names></name><name><surname>Borrayo-Sanchez</surname><given-names>G</given-names></name></person-group><article-title>Genetic factors of the hemostatic system in young patients with myocardial infarction</article-title><source>Cir Cir</source><year>2010</year><volume>78</volume><issue>1</issue><fpage>93</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20226135</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palafox-Sanchez</surname><given-names>CA</given-names></name><name><surname>Vazquez-Del Mercado</surname><given-names>M</given-names></name><name><surname>Orozco-Barocio</surname><given-names>G</given-names></name><name><surname>Garcia-De la Torre</surname><given-names>I</given-names></name><name><surname>Torres-Carrillo</surname><given-names>N</given-names></name><name><surname>Torres-Carrillo</surname><given-names>NM</given-names></name><etal/></person-group><article-title>A functional Ser(413)/Ser(413) PAI-2 polymorphism is associated with susceptibility and damage index score in systemic lupus erythematosus</article-title><source>Clin Appl Thromb Hemost</source><year>2009</year><volume>15</volume><issue>2</issue><fpage>233</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1177/1076029607308868</pub-id><pub-id pub-id-type="pmid">18818228</pub-id></element-citation></ref></ref-list></back></article>